1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Autoimmune Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Constantinescu, CS; Edwards, LJ | 1 |
| Andrews, L; Bonvini, E; Flaherty, MM; Garman, R; Johnson, S; MacLachlan, TK; Magee, T; Stein, KE; Troutt, M; Tuaillon, N | 1 |
| Day, JR; Ghimire, G; Leong, HS; Mahesh, BM; McCormack, AD; Podor, TJ; Rose, ML; Smith, JD | 1 |
| Willoughby, JB; Willoughby, WF | 1 |
| Baskin, DG; Braquet, P; Goodner, CJ; Jobe, LW; Lernmark, A; Ubungen, R | 1 |
| Giers, G; Janzarik, H; Kempe, ER; Mueller-Eckhardt, C | 1 |
| Kanaji, K; Okuma, M; Sensaki, S; Sugiyama, T; Uchino, H; Ushikubi, F | 1 |
2 review(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Autoimmune Disease
| Article | Year |
|---|---|
Platelet activating factor/platelet activating factor receptor pathway as a potential therapeutic target in autoimmune diseases.
Topics: Animals; Autoimmune Diseases; Humans; Inflammation; Platelet Activating Factor; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Signal Transduction | 2009 |
Immunologic mechanisms of parenchymal lung injury.
Topics: Animals; Arachidonic Acids; Arthus Reaction; Autoimmune Diseases; Biotransformation; Complement System Proteins; Disease Models, Animal; Free Radicals; Humans; Immune Complex Diseases; Lung Diseases; Lymphokines; Platelet Activating Factor | 1984 |
5 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Autoimmune Disease
| Article | Year |
|---|---|
Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice.
Topics: Animals; Antibodies, Monoclonal, Humanized; Autoimmune Diseases; Blood Platelets; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Flow Cytometry; GPI-Linked Proteins; Humans; Immunoglobulin G; Leukocyte Count; Male; Mice; Mice, Transgenic; Neutrophils; Platelet Activating Factor; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Receptors, IgG | 2012 |
Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor.
Topics: Apoptosis; Autoantibodies; Autoimmune Diseases; Blood Platelets; Cell Adhesion; Complement C3d; Culture Media, Conditioned; Fibrinogen; Humans; Immunoglobulin M; Immunosorbent Techniques; Leukocytes; P-Selectin; Platelet Activating Factor; Platelet Activation; Pyridinium Compounds; Recombinant Proteins; Thrombophilia; Thromboplastin; Vimentin | 2008 |
Protection from BB rat diabetes by the platelet-activating factor inhibitor BN50730.
Topics: Age Factors; Animals; Autoimmune Diseases; Azepines; Diabetes Mellitus, Type 1; Insulin; Islets of Langerhans; Male; Platelet Activating Factor; Rats; Rats, Inbred BB; Tetrazoles; Thienopyridines; Thyroid Gland; Thyroiditis, Autoimmune; Triazoles | 1993 |
Failure of the platelet-activating-factor antagonist WEB 2086 BS for treatment of chronic autoimmune thrombocytopenia.
Topics: Adult; Aged; Autoimmune Diseases; Azepines; Chronic Disease; Drug Evaluation; Female; Humans; Male; Middle Aged; Platelet Activating Factor; Prospective Studies; Thrombocytopenia; Triazoles | 1990 |
A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia.
Topics: Autoimmune Diseases; Blood Coagulation Factors; Blood Platelet Disorders; Collagen; Female; Humans; Immunoglobulin G; Middle Aged; Platelet Activating Factor; Platelet Aggregation; Purpura, Thrombocytopenic; Thrombocytopenia; Thromboxane B2 | 1987 |